Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
46.96
-0.36 (-0.76%)
Dec 20, 2024, 4:00 PM EST - Market closed
Halozyme Therapeutics Revenue
Halozyme Therapeutics had revenue of $290.08M in the quarter ending September 30, 2024, with 34.28% growth. This brings the company's revenue in the last twelve months to $947.36M, up 21.35% year-over-year. In the year 2023, Halozyme Therapeutics had annual revenue of $829.25M with 25.62% growth.
Revenue (ttm)
$947.36M
Revenue Growth
+21.35%
P/S Ratio
6.32
Revenue / Employee
$2,539,826
Employees
373
Market Cap
5.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 829.25M | 169.14M | 25.62% |
| Dec 31, 2022 | 660.12M | 216.81M | 48.91% |
| Dec 31, 2021 | 443.31M | 175.72M | 65.67% |
| Dec 31, 2020 | 267.59M | 71.60M | 36.53% |
| Dec 31, 2019 | 195.99M | 44.13M | 29.06% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Grifols | 7.81B |
| Bausch + Lomb | 4.68B |
| Elanco Animal Health | 4.45B |
| Lantheus Holdings | 1.50B |
| Merit Medical Systems | 1.33B |
| Stevanato Group | 1.22B |
| Waystar Holding | 906.14M |
| Legend Biotech | 520.18M |
HALO News
- 24 days ago - Halozyme to Present at Upcoming Investor Conferences - PRNewsWire
- 4 weeks ago - Halozyme withdraws $2.1 bln buyout offer for Evotec - Reuters
- 4 weeks ago - Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions - PRNewsWire
- 4 weeks ago - Halozyme says €2 billion takeover of Evotech would create leader in drug discovery - Market Watch
- 4 weeks ago - Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec - PRNewsWire
- 5 weeks ago - Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion - Benzinga
- 5 weeks ago - Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction - PRNewsWire
- 5 weeks ago - Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports - Reuters